Avascular necrosis (AVN) of the femoral head can result from high-dose corticosteroid therapy. Given that severe COVID-19 pneumonia patients respond positively to corticosteroids, this study aimed to explore the incidence of femoral head AVN associated with corticosteroid therapy in 24 patients diagnosed with severe COVID-19 at a single center. The study included 24 patients who were diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection through real-time reverse transcription polymerase chain reaction test (rRT-PCR) and with COVID-19 pneumonia via high-resolution computed tomography (HRCT). Moderate cases received 2×4 mg Dexamethasone while severe cases were also administered with 3×40 mg Methylprednisolone. Diagnosis of femoral head AVN was confirmed with magnetic resonance imaging (MRI) and radiographs, which was subsequently treated by a total hip arthroplasty (THA) or a core decompression surgery (CDS) in line with the Ficat and Arlet classifications. Among the patients, 8 had a moderate infection course, while 16 were severe. The mean corticosteroid duration was 15±5 days for Dexamethasone and 30 days for Methylprednisolone. Severe patients presented with higher grade femoral head AVN and greater pain levels compared to moderate cases (p<0.05). Four patients developed bilateral AVN. The treatment resulted in 23 THAs and 5 CDSs. The data from this study corroborate earlier studies and case reports, suggesting an increased occurrence of AVN of the femoral head during the COVID-19 pandemic due to the high-dose corticosteroid therapy employed for patients hospitalized with severe COVID-19 pneumonia.
Background /Objectives: Periprosthetic joint infection (PJI) has no gold standard. Accuracy studies borrow one of several composite definitions instead, and these definitions do not label the same patients as infected. We asked how often accuracy studies say which definition they used, and how far the choice moves the numbers they report. Methods: In this systematic review, we searched PubMed on 20 October 2026 for primary accuracy studies of PJI tests and classified each abstract by the reference definition it named. Studies that applied two or more definitions (MSIS 2011/2013, ICM 2018, IDSA 2013, EBJIS proposed or 2021) to the same cohort were assessed further, and accuracy was extracted per definition. Ratios of PJI cases and the change in sensitivity of the alpha-defensin test were pooled with random-effects models. Results: Of 1744 accuracy studies, 437 (25%) named a reference definition in the The share rose from none before 2012 to 35% from 2021 onward. Seventeen studies reported accuracy under more than one definition in the same patients. EBJIS classified 1.47 times as many patients as infected as MSIS (95% CI 1.33–1.62; 6 cohorts; I2 = 4%) and 1.26 times as many as ICM 2018 (1.08–1.46; 6 cohorts; I2 = 58%). The pooled sensitivity of the alpha-defensin test was 85.6% (76.9–91.4) against MSIS and 56.3% (48.6–63.7) against EBJIS in the same three cohorts, while specificity stayed between 89% and 100%. Across 13 test–cohort pairs, the median change in sensitivity when the reference moved to EBJIS was −18.5 percentage points (IQR −29.0 to −4.9); sensitivity fell in 10 pairs and changed by less than 3 points in three. Conclusions: For several PJI tests, the reported sensitivity depends substantially on the reference definition chosen. A definition that labels more patients as infected is not, for that reason, a more accurate one. Accuracy figures obtained under different definitions should not be pooled or compared as if they measured the same thing, and every accuracy study should name its reference definition in the
Background: Total hip arthroplasty (THA) and the diagnosis of periprosthetic joint infection (PJI) have each acquired a technology that measures with high precision: intraoperative navigation, which reports component position to within a few degrees, and molecular methods, which identify the infecting organism and the host response at genomic resolution. Objective: To establish whether the measured accuracy has been shown to reach the patient as a clinical outcome. Methods: This is a narrative review, reported according to SANRA. MEDLINE, Scopus, and Web of Science databases were searched from inception to 31 August 2026. English-language studies in humans were eligible if they reported positional or diagnostic accuracy, a patient-level clinical or economic outcome after THA or after treatment of PJI or osteomyelitis, or a factor modifying the relation between the two. Animal, in vitro, and cadaveric studies, conference abstracts, and reports without extractable data were excluded. Forty studies were included. No pooled estimate was calculated, and no new statistical analysis was performed. Results: Navigation reduced positional outliers consistently, but in two matched claims-based cohorts of patients with morbid obesity (4499 and 5835 patients), it was not associated with lower rates of PJI, dislocation, periprosthetic fracture, mechanical loosening, or revision within two years. Candidate immunogenetic variants in osteomyelitis have never been tested against a treatment decision. Metagenomic sequencing was no more accurate than culture (sensitivity 63.2% versus 68.4%; specificity 80.0% versus 95.0%) except after antibiotic exposure. Reported infection rates and test accuracy both change with the case definition applied. Conclusions: In both settings, the limiting factor is the design of the studies linking measurement to outcome rather than the precision of the measurement.